<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70410">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779141</url>
  </required_header>
  <id_info>
    <org_study_id>PL01</org_study_id>
    <nct_id>NCT01779141</nct_id>
  </id_info>
  <brief_title>Orchestra Pregnancy Observational Study in Poland</brief_title>
  <official_title>A Multi-center Observational Study During Pregnancy for Women With T1DM Treated With the Paradigm Insulin Pumps Donated by the 'Wielka Orkiestra Świątecznej Pomocy' Foundation in Poland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Poland Spółka z ograniczoną odpowiedzialnością</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Poland Spółka z ograniczoną odpowiedzialnością</source>
  <oversight_info>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      The aim of this observational study (registry) is to document the use of insulin pump
      therapy (CSII) and sensor augmented pump therapy (SAP) before, during and after pregnancy in
      women with Type 1 Diabetes Mellitus benefiting from the Orchestra donation of Paradigm
      REAL-Time and Paradigm Veo pumps in Poland.

      Objectives:

      To assess the benefits of CSII and SAP on the maternal glycemic control; To assess the
      prevalence of pregnancy complications (rates of preterm delivery, infant birth weight,
      neonatal care admissions) from preconception phase, throughout pregnancy, during delivery
      and after delivery during lactation phase (up to 6 weeks); To report and assess the
      potential benefits of SAP or CSII on neonatal outcomes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>16 Months</target_duration>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>16 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maternal glycemic control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of prevalence of pregnancy complications and neonatal outcomes</measure>
    <time_frame>During pregnancy, at delivery and 6 weeks after delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mode of delivery (rates elective and emergency CS, normal), Respiratory distress (1 and 5 minute Apgar scores), Gestational age at delivery, % preterm delivery &lt;37 weeks, Infant birth weight (SD scores and customised birth weight percentile, % large for gestational age (LGA), % small for gestational age (SGA), Neonatal morbidity (treatment for neonatal hypoglycaemia), Neonatal care admission (duration of stay, level of care), Pregnancy related serious adverse events (miscarriage &lt;22 weeks, congenital malformation, stillbirth, neonatal death), Feeding at hospital discharge (breast, bottle, both)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Pregnancy</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, urine samples as required in routine practice before, during and after
      pregnancy in women with Type 1 Diabetes Mellitus
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with Type 1 Diabetes Mellitus planning pregnancy or being pregnant until the 16th
        week of pregnacy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female Diagnosed with Diabetes Mellitus Type 1

          -  Subject indicated by Health Care Provider (HCP) to start insulin pump therapy (CSII)
             or sensor augmented pump therapy (SAP) due to the desired or established pregnancy

          -  HCP has prescribed the use of Orchestra donated device to the subject independently
             of the study

          -  Signed Patient Informed Consent (PIC)

          -  Subject is 18 to 45 years old, planning immediate pregnancy (within the next 6
             months) or being pregnant within the first trimester until the 16th week of
             amenorrhea

          -  Subject has been on Multiple Daily Injections (MDI) for at least 3 months (before
             pre-conception phase), except following a miscarriage and trying another pregnancy

        Exclusion Criteria:

          -  Participation in any other clinical trial - currently and/or in the last 3 months
             before the signature of PIC

          -  Subject uses an insulin pump that was not donated by the Orchestra foundation

          -  Use of contraception during insulin pump therapy

          -  Pregnant women with longer than 16 weeks of pregnancy/amenorrhea

          -  Subjects who need assisted in vitro fertilization

          -  Subjects with Diabetes Mellitus Type 2

          -  Subjects with Gestational Diabetes or MODY

          -  Subject under the age of 18

          -  Subject legally incompetent

          -  Subject cannot read or write
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Sieradzki, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cracow Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Telejko, MD</last_name>
      <phone>+48 602 399 997</phone>
      <email>telejkob@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Beata Telejko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny</name>
      <address>
        <city>Białystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Arciszewska, MD</last_name>
      <phone>+48 501 700 730</phone>
      <email>wizumalgorzata@arciszewska.eu</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Arciszewska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Bielsku Białej</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Petrulewicz-Salamon, MD</last_name>
      <phone>+48 696 484 620</phone>
      <email>ipetrulewicz@hospital.com.pl</email>
    </contact>
    <investigator>
      <last_name>Iwona Petrulewicz-Salamon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bygdoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Sokup, MD</last_name>
      <phone>+48 509 217 662</phone>
      <email>alinasokup@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Alina Sokup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Jaśle</name>
      <address>
        <city>Jaslo</city>
        <zip>38-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gorczyca-Pluta, MD</last_name>
      <phone>+48 604 637 952</phone>
      <email>martagp@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Marta Gorczyca-Pluta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ WITAMED Outpatient Diabetes Clinic</name>
      <address>
        <city>Kielce</city>
        <zip>25-035</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grażyna Majcher-Witczak, MD</last_name>
      <phone>+48 604 630 953</phone>
      <email>witczak@canea.com.pl</email>
    </contact>
    <investigator>
      <last_name>Grażyna Majcher-Witczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemysław Witek, MD</last_name>
      <phone>+48 609 968 989</phone>
      <email>przemyslawwitek@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Przemysław Witek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 Uniwersytetu Medycznego w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Matyjaszek-Matuszek, MD</last_name>
      <phone>+48 604 302 289</phone>
      <email>bmm@2com.pl</email>
    </contact>
    <investigator>
      <last_name>Beata Matyjaszek-Matuszek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Rutkowska, MD</last_name>
      <phone>+48 605 602 160</phone>
      <email>rutkowskaj@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Joanna Rutkowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PSZOZ Wojewódzkie Centrum Medyczne w Opolu</name>
      <address>
        <city>Opole</city>
        <zip>45-418</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Urbanska, MD</last_name>
      <phone>+48 506 267 679</phone>
      <email>wanda_u@op.pl</email>
    </contact>
    <investigator>
      <last_name>Wanda Urbanska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zakład Opieki Zdrowotnej Poznań-Jeżyce</name>
      <address>
        <city>Poznan</city>
        <zip>60-834</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Pisarczyk-Wiza, MD</last_name>
      <phone>+48 502 041 751</phone>
      <email>wizus@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Dorota Pisarczyk-Wiza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic of Gynecology and Obstetrics of Marcinkowski Medical University</name>
      <address>
        <city>Poznań</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Wender-Ożegowska, Prof</last_name>
      <phone>+48 501 276 060</phone>
      <email>ewaoz@post.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Wender-Ożegowska, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-301</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Kedzierska, MD</last_name>
      <phone>+48 502 222 391</phone>
      <email>joanna.kedzierska@onet.eu</email>
    </contact>
    <investigator>
      <last_name>Joanna Kedzierska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie im. Marii Skłodowskiej-Curie</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Ogonowski, MD</last_name>
      <phone>+48 608 221 899</phone>
      <email>jogonowski@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Jaroslaw Ogonowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zespolony im. L. Rydygiera</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elzbieta Szymanska, MD</last_name>
      <phone>+48 601 644 766</phone>
      <email>elzbieta-szymanska8@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Elzbeita Szymanska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Puchta, MD</last_name>
      <phone>+48 604 498 013</phone>
      <email>mpuchta@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Puchta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. ks. Anny Mazowieckiej Warszawskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Warszawa</city>
        <zip>00-315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneta Malinowska-Polubiec, MD</last_name>
      <phone>+48 609 493 935</phone>
      <email>anetapolubiec@interia.eu</email>
    </contact>
    <investigator>
      <last_name>Aneta Malinowska-Polubiec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Wojewódzki Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabela Razna, MD</last_name>
      <phone>+48 608 652 646</phone>
      <email>driza@tlen.pl</email>
    </contact>
    <investigator>
      <last_name>Izabela Raźna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Zespół Specjalistycznej Opieki Zdrowotnej</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-403</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Sowinski, MD</last_name>
      <phone>+48 501 424 165</phone>
      <email>drdariuszsowinski@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dariusz Sowinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 im prof. Stanisława Szyszko</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edyta Cichocka, MD</last_name>
      <phone>+48 606 943 038</phone>
      <email>sedyta@mp.pl</email>
    </contact>
    <investigator>
      <last_name>Edyta Cichocka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zespół Wojewódzkich Przychodni Specjalistycznych w Katowicach</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Wróbel, MD</last_name>
      <phone>+48 606 873 060</phone>
      <email>wrubella@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Marta Wróbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ MED-ART Poradnie Specjalistyczne Sp. z o.o.</name>
      <address>
        <city>Zory</city>
        <zip>44-240</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violetta Szostek-Gawel, MD</last_name>
      <phone>+48 501 616 115</phone>
      <email>vszostekgawel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Violetta Szostek-Gawel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elektra Szymanska-Garbacz, MD</last_name>
      <phone>+48 600 435 885</phone>
      <email>etkag@op.pl</email>
    </contact>
    <investigator>
      <last_name>Elektra Szymanska-Garbacz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytet Medyczny w Łodzi, Klinika Diabetologii</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Cypryk, Professor</last_name>
      <phone>+48 502 150 273</phone>
      <email>kcypryk@mp.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Cypryk, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes Mellitus - T1DM</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Insulin Pump</keyword>
  <keyword>Glucose Sensor</keyword>
  <keyword>Continuous Subcutaneous Insulin Infusion - CSII</keyword>
  <keyword>Sensor Augmented Pump - SAP</keyword>
  <keyword>Continuous Glucose Monitoring - CGM</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
